|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 9/00 | |
| A61K 47/38 | |||
| A61K 31/56 | |||
| A61K 31/58 | |||
| A61P 11/02 | |||
| A61P 5/44 |
| (11) | Patento numeris | 1478340 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 03737365.1 |
| Europos patento paraiškos padavimo data | 2003-02-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2004-11-24 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-09-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2003/000504 |
| Data | 2003-02-04 |
| (87) | Numeris | WO 2003/066024 |
| Data | 2003-08-14 |
| (30) | Numeris | Data | Šalis |
| 67020 | 2002-02-04 | US |
| (72) |
BIGGADIKE, Keith, GB
BUXTON, Ian, CA
COOTE, Steven, John, GB
NICE, Rosalyn, Kay, GB
REED, Kenton, Lewis, CA
SAYANI, Amyn, CA
SHARMA, Avinash, Chander, CA
|
| (73) |
Glaxo Group Limited,
980 Great West Road, Brentford, Middlesex TW8 9GS,
GB
|
| (54) | Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions |
| Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions |